Synthesis and biological activity of olomoucine II.

Article Details

Citation

Krystof V, Lenobel R, Havlicek L, Kuzma M, Strnad M

Synthesis and biological activity of olomoucine II.

Bioorg Med Chem Lett. 2002 Nov 18;12(22):3283-6.

PubMed ID
12392733 [ View in PubMed
]
Abstract

Based on our previous experiences with synthesis of purines, novel 2,6,9-trisubstituted purine derivatives were prepared and assayed for the ability to inhibit CDK1/cyclin B kinase. One of newly synthesized compounds designated as olomoucine II, 6-[(2-hydroxybenzyl)amino]-2-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine, displays 10 times higher inhibitory activity than roscovitine, potent and specific CDK1 inhibitor. Olomoucine II in vitro cytotoxic activity exceeds purvalanol A, the most potent CDK inhibitor, as it kills the CEM cells with IC(50) value of 3.0 microM.

DrugBank Data that Cites this Article

Binding Properties
DrugTargetPropertyMeasurementpHTemperature (°C)
OlomoucineCyclin-dependent kinase 1IC 50 (nM)7000N/AN/ADetails
SeliciclibCyclin-dependent kinase 1IC 50 (nM)450N/AN/ADetails